The assay combines the scalability and automation of the Ella platform with AAV reagents from Progen, according to Bio-Techne. It features hands-free automation and utilizes Progen's recombinant AAV2 antibody (A20R) to quantify assembled AAV2 capsids. Also, the assay is designed to minimize variability and ensure optimum and consistent quantitation throughout the viral purification process, the company noted.

Bio-Techne launches multiplex spatial genomics assay
Bio-Techne has expanded its RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed,...

Bio-Techne opens new facility in Ireland
Bio-Techne has opened a new facility in Dublin as part of its efforts to support the life sciences industry in Europe.

Catamaran Bio, Bio-Techne expand CAR-NK cell collaboration
Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing...

Bio-Techne joins Cell and Gene Therapy Catapult PAT consortium
Bio-Techne is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies,...

Thermo Fisher to sell Progen primary antibodies
Gene therapy tools manufacturer Progen Biotechnik has signed a nonexclusive distribution agreement with Thermo Fisher Scientific.